Mitochondrial Myopathy Diagnosis & Treatment Market Research Report- Global Forecast till 2020

Mitochondrial Myopathy Diagnosis & Treatment Market Research Report- Global Forecast till 2020

ID: MRFR/HC/2648-CRR | June, 2017 | Region: Global | 61 pages | Cooked Research Reports

Mitochondrial Myopathy Diagnosis & Treatment Market Information: By Type (MELAS, PEO, MERRF, MNGIE, KSS, MDS, NARP) By Diagnostic Tests (genetic tests, muscle biopsy) By Therapy (Supportive Therapy, Targeted Therapy) - Global Forecast Till 2020  


Market Synopsis of Global Mitochondrial myopathy diagnosis & treatment Market:


Market scenario:


Mitochondrial myopathies are associated with mitochondrial diseases which are caused by certain nuclear DNA deletions and mutations. Mitochondrial myopathies affect mitochondria which is responsible for energy production within a cell associated with mitochondrial disease. Thus, they cause low energy and free radical production which results in a variety of symptoms.


The factors such as rising number of screening services for mitochondrial disorders, growing number of mitochondrial myopathy cases, increased government funding and incentives for rare genetic diseases are driving the market for mitochondrial myopathy diagnosis & treatment. However, poor treatment options and absence of curative treatment have constrained the market.


Considering all these factors, the market for mitochondrial myopathy diagnosis & treatment is expected to reach $ 33.6 million by the end of 2020, this market is projected to growing at a CAGR of ~ 9.82 % during 2017-2020.



Key Findings:



  • Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) and Progressive External Ophthalmoplegia (PEO) are the most commonly found conditions in patients with mitochondrial myopathy. The global MELAS diagnosis & treatment market is expected to grow at the CAGR of 19.39% during 2021 to 2025.

  • Genetic tests accounted for the largest market share in 2016, and is projected to grow at a CAGR of 10.11% during 2017 to 2020.

  • Supportive therapy captured the whole market share in 2016, and is projected to grow at a CAGR of 9.82% during 2017 to 2020.



Research methodology                                                                                     

 


Sources: Genetic and Rare Diseases Information Center (GARD), Orphanet, The United Mitochondrial Disease Foundation (UMDF), World health Organization (WHO), Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation.

Intended Audience



  • Global Mitochondrial myopathy diagnosis & treatment solutions, manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities



Figure 1         Global Mitochondrial myopathy diagnosis & treatment Market by Type, 2016 (% Market Share)


 


Segments:


The global mitochondrial myopathy diagnosis & treatment market is segmented on the basis of type, diagnostic tests and therapy. Based on type, the market has been segmented as mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), progressive external ophthalmoplegia (PEO), myoclonic epilepsy with ragged red fibres (MERRF), mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE), Kearns–Sayre syndrome (KSS), mitochondrial DNA depletion syndrome (MDS), Pearson syndrome, Leigh syndrome, neuropathy, ataxia, and retinitis pigmentosa (NARP). Based on the diagnostic tests, the market has been segmented as genetic tests, muscle biopsy and biochemical test. Based on the therapy, the market has been segmented as supportive therapy and targeted therapy.



Regional analysis


The Americas account for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. The Americas mitochondrial myopathy diagnosis & treatment market is expected to reach USD 116.7 million by the end of 2025 at the CAGR of 19.39% during 2017 to 2025. The faster market uptake of new technology in the US is also an important driver of the market for global mitochondrial myopathy diagnosis & treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Asia Pacific mitochondrial myopathy diagnosis & treatment market is expected to reach USD 4.4 million by the end of 2025 at the CAGR of 9.94% during 2017 to 2020. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.



Key players of Global Mitochondrial myopathy diagnosis & treatment Market:


Key players profiled in the report are Centogene AG, GeneDx, Ixchel Pharma, Khondrion BV, Mitobridge, NeuroVive Pharmaceutical AB, Reata Pharmaceuticals Inc., Stealth Biotherapeutics and others.


The report for Global Mitochondrial myopathy diagnosis & treatment Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
TABLE OF CONTENTS

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.4.1 Assumptions

1.4.2 Limitations

1.5 Market Structure

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3.1 Introduction

3.2 Drivers

3.2.1 Rise in number of mitochondrial myopathy incidence rate and growing number of screening services.

3.2.2 Government funding and incentives for rare genetic diseases

3.3 Restraints

3.3.1 Poor treatment options and absence of curative treatment

3.3.2 Lack of awareness and diagnosis of the rare mitochondrial disorders

3.4 Opportunities

3.4.1 Faster market uptake and low marketing cost

3.4.2 Research and development

3.5 Challenges

3.5.1 Rare nature of the disease

3.5.2 Poor understanding of mitochondria and genetics

3.5.3 Cost of drug development and high investment risk

4.1 Porter’s Five Forces Analysis

4.1.1 Threat from a New Entrant

4.1.2 Bargaining Power of Buyer

4.1.3 Bargaining Power of Supplier

4.1.4 Threat from substitute

4.1.5 Intensity of Competitive Rivalry

4.2 Pipeline Analysis

4.2.1 Introduction

4.2.2 KH176

4.2.3 Elamipretide

4.2.4 RTA 408

4.2.5 IXC 103

4.2.6 NV556

4.3 Mega Trends

4.3.1 Strategies for increasing mitochondrial biogenesis

4.3.2 Antioxidant approaches

4.3.3 Targeting mitochondrial dynamics and biogenesis

4.3.4 Mitochondrial membrane lipids as therapeutic targets

4.3.5 Nucleoside replacement and gene therapy

4.3.6 Enzyme replacement therapy

4.4 Investment Opportunity Analysis

4.4.1 Market size (current and future), growth rate, and profitability

4.4.2 Investment Risks

4.4.3 Market Outlook

4.4.4 Competitors

4.4.5 Projections

5.1 Introduction

5.2 Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

5.3 Progressive External Ophthalmoplegia (PEO)

5.4 Myoclonic Epilepsy with Ragged Red Fibres (MERRF)

5.5 Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE)

5.6 Kearns–Sayre Syndrome (KSS)

5.7 Mitochondrial DNA Depletion Syndrome (MDS)

5.8 Pearson Syndrome

5.9 Leigh Syndrome

5.10 Neuropathy, Ataxia, and Retinitis Pigmentosa (NARP)

6.1 Introduction

6.2 Genetic Tests

6.3 Muscle Biopsy

6.4 Biochemical Test

7.1 Introduction

7.2 Supportive Therapy

7.3 Targeted Therapy

8.1 Introduction

8.2 Americas

8.3 Europe

8.4 Asia-Pacific

8.5 Middle East & Africa

9.1 AbbVie Inc.

9.1.1 Company Overview

9.1.2 Product Overview

9.1.3 Financial Overview

9.2 Centogene AG

9.2.1 Company Overview

9.2.2 Product Overview

9.2.3 Financial Overview

9.2.4 Key Development

9.3 GeneDx

9.3.1 Company Overview

9.3.2 Product Overview

9.3.3 Financial Overview

9.3.4 Key Development

9.4 Ixchel Pharma

9.4.1 Company Overview

9.4.2 Product Overview

9.4.3 Financial Overview

9.5 Khondrion BV

9.5.1 Company Overview

9.5.2 Product Overview

9.5.3 Financial Overview

9.5.4 Key Development

9.6 Mitobridge

9.6.1 Company Overview

9.6.2 Product Overview

9.6.3 Financial Overview

9.7 NeuroVive Pharmaceutical AB

9.7.1 Company Overview

9.7.2 Product Overview

9.7.3 Financial Overview

9.7.4 Key Development

9.8 Reata Pharmaceuticals Inc.

9.8.1 Company Overview

9.8.2 Product Overview

9.8.3 Financial Overview

9.9 Stealth Biotherapeutics

9.9.1 Company Overview

9.9.2 Product Overview

9.9.3 Financial Overview

9.9.4 Key Developments

TABLE 1 MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET: PIPELINE ANALYSIS 23
TABLE 2 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET, BY TYPE, 2014 -2020 (USD MILLION) 34
TABLE 3 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET, BY TYPE 2021 - 2025 (USD MILLION) 35
TABLE 4 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET, BY DIAGNOSTIC TEST, 2014-2020 (USD MILLION) 38
TABLE 5 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET, BY DIAGNOSTIC TEST, 2021-2025 (USD MILLION) 38
TABLE 6 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET, BY THERAPY, 2014-2020 (USD MILLION) 40
TABLE 7 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET, BY THERAPY, 2021-2025 (USD MILLION) 41
TABLE 8 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET, BY REGION, 2014-2020 (USD MILLION) 43
TABLE 9 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET, BY REGION, 2021-2025 (USD MILLION) 44
TABLE 10 AMERICAS MITOCHONDRIAL MYOPATHIES DIAGNOSIS & TREATMENT MARKET, BY REGION, 2014-2020 (USD MILLION) 44
TABLE 11 AMERICAS MITOCHONDRIAL MYOPATHIES DIAGNOSIS & TREATMENT MARKET, BY REGION, 2021-2025 (USD MILLION) 45
TABLE 12 EUROPE MITOCHONDRIAL MYOPATHIES DIAGNOSIS & TREATMENT MARKET, BY REGION, 2014-2020 (USD MILLION) 45
TABLE 13 EUROPE MITOCHONDRIAL MYOPATHIES DIAGNOSIS & TREATMENT MARKET, BY REGION, 2021-2025 (USD MILLION) 46
TABLE 14 ASIA PACIFIC MITOCHONDRIAL MYOPATHIES DIAGNOSIS & TREATMENT MARKET, BY REGION, 2014-2020 (USD MILLION) 47
TABLE 15 ASIA PACIFIC MITOCHONDRIAL MYOPATHIES DIAGNOSIS & TREATMENT MARKET, BY REGION, 2021-2025 (USD MILLION) 47
TABLE 16 MIDDLE EAST & AFRICA MITOCHONDRIAL MYOPATHIES DIAGNOSIS & TREATMENT MARKET, BY REGION, 2014-2020 (USD MILLION) 48
TABLE 17 MIDDLE EAST & AFRICA MITOCHONDRIAL MYOPATHIES DIAGNOSIS & TREATMENT MARKET, BY REGION, 2021-2025 (USD MILLION) 48

FIGURE 1 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET: MARKET STRUCTURE 11
FIGURE 2 RESEARCH PROCESS OF MRFR 12
FIGURE 3 FORECAST INDICATORS 14
FIGURE 4 PORTERS FIVE FORCES MODEL 19
FIGURE 5 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET BY TYPE, 2016, 2021 & 2025 (USD MILLION) 34
FIGURE 6 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET BY DIAGNOSTIC TEST, 2016, 2021 & 2025 (USD MILLION) 37
FIGURE 7 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET BY THERAPY, 2016, 2021 & 2025 (USD MILLION) 40
FIGURE 8 GLOBAL MITOCHONDRIAL MYOPATHY DIAGNOSIS & TREATMENT MARKET BY REGION, 2016, 2021 & 2025 (USD MILLION) 43
FIGURE 9 ABBVIE: RECENT FINANCIAL 49
FIGURE 10 ABBVIE: GEOGRAPHIC MIX, 2016 (%) 50
FIGURE 11 NEUROVIVE PHARMACEUTICAL AB: RECENT FINANCIALS 56
FIGURE 12 REATA PHARMACEUTICALS: RECENT FINANCIALS 58
FIGURE 13 REATA PHARMACEUTICALS: R&D EXPENSES, 2016 (%) 59